TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants who complete the sessions and questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prostate-specific antigen (PSA) response rate of ≥50% decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mansoura Early Feeding Skills Assessment (MEFSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibreoptic Endoscopic Evaluation of swallowing (FEES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verified Detection Rate for Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Verified Detection Rate for Invasive Lobular Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose (MTD)/Recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Planar late Heart to Mediastinal Ratio (MIBG imaging)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in HRV with mental stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in pre-ejection period (PEP) with mental stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tampa Scale for Kinesiophobia-11 (TSK-11)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of relevant echocardiographic parameter z scores > 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Revised Hammersmith Scale (RHS) total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: blockade of tube advancement during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Who Reach Amyloid Plaque Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Non alcoholic fatty liver fibrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Regional lung function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with Dose Limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Adverse Events (AEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of abnormal respiratory mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of poorly ventilated lung areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Validity of OxVPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of OxVPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changing in endogenous insulin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changing in insulin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of anti-HDV and HDV RNA tests performed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of anti-HDV and HDV RNA tests expected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in measured blood indices (pH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in measured blood indices (pO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in measured blood indices (pCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in measured blood indices (CHO3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in measured blood indices (lactate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: m6A modification of mRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expression level of mRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of methylated mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of RNA methyltransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Soft Tissue Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 12-Lead Electrocardiogram
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient-reported disease-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total volumetric mineral density by HR-pQCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: trabecular volumetric mineral density by HR-pQCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Cortical volumetric mineral density by HR-pQCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and mineral outcomes
Primary endpoint: Prevalence of neurocognitive decline (changes in z-scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adhesive remnant index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stigma Resistance Scale (SRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Substance Abuse Self-Stigma Scale (SASSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Prospective Participants Eligible for Participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of treatment with regorafenib monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frontal knee range of motion during stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who completed the questionnaires at both assessments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Discrimination of cardiac caused dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best response to GD2CART cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal microbial composition and diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of POCUS for the diagnosis of acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of POCUS plus Eko for the diagnosis of acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Agreement between POCUS and Eko CORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in gaze pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Methemoglobin (MetHb) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: soft tissue changes around implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax of ADC189/ADC189-I07
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of ADC189/ADC189-I07
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleural pressure (Ppl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who experienced Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: maximum administered dose (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak subjective opioid withdrawal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in minutes until a Subjective Opioid Withdrawal (SOWS) score of more than 11 is reached
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil diameter nadir size as measured in millimeters (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Fatigue Score (T-Score)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proximal sessile serrated lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of uncomplicated malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility of completing all clinical trial activities and follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Predictive value score of imagery markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stimulated C-peptide during a MMTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in produce intake
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Extent of pain recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Magnetic Resonance Imaging (fMRI) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine Toxicology: opioid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabecular scleral-spur angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean EBV neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sexual mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aggregate specimen length (ASL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Repeated Thoracocentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: keratinized gingival thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: keratinized gingival width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival recession width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of successful weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micropore Depth, Upper Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Micropore Depth, Volar Forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Micropore Depth, Palm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Muscular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent NEXUS-Negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health behavior stage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Dose-Limiting Toxicities (DLTs) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) Assessed by Investigator with RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15% decline in forced expiratory volume in males
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 15% decline in forced expiratory volume in females
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Real World Time to Next Treatment (rwTTNT)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of Illuminare-1
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of paracetamol and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Meeting Immune Serological Response Criteria to Tetanus Toxoid Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Meeting Immune Serological Protection Criteria to Tetanus Toxoid Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean post-operative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving serum phosphate levels within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of adverse events (AEs) / serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Repigmentation of the target area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of True positive results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of False positive results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of True negative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of False negative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gene Expression as Measured by Counts of Transcript per Million Reads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success on the IGA of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first need of opiate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hepatic fibrosis change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic injury change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful examination percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in days of stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent improvement of NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: difference of NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percent improvement of MRC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: difference of MRC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety outcome: Side effect
Endpoint domain: Adverse events/effects
Primary endpoint: Safety outcome: discontinuing patients
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Completing Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with pulmonary hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: System Usability Score (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of the tool-in-lesion confirmation scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiota profile assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who develop dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective rating of fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastrointestinal distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urges to restrict food intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change From Baseline in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number and percentage of participants with solicited local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants with solicited systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers and percentages of participants with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of time with severe hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Hyperglycemia Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Disease development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of intramyocardial fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of delayed enhanced CT detected scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantification of delayed enhanced CT detected scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Hemoglobin (Hb) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Rate of Sickle Cell Pain Crises (SCPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory assess and treat (RAAT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Headaches and migraines per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIT6 scores (disability score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAD (anxiety/depression score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of alirocumab
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of gut microbiota richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Composite of PROMIS Depression and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum C4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Satisfaction with Anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole brain cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declarative Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: leucine content in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events (AE) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with study success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schiff Cold Air Sensitivity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain at 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first CompEx Asthma event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: First Pass Reperfusion Effect (FPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatomal level of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Growth Velocity (AGV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return of responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time of the 5 repeated sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes